University of Kansas Medical Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1906-01-01

Employees: 5K

Market Cap: -

Website: https://www.kumc.edu

Clinical Trials

Rural Women Connecting for Better Health

Not Applicable

Completed

Conditions: Breast Cancer
Obesity

Interventions: Behavioral: Newsletter
Behavioral: Group phone counseling

First Posted Date: 2011-09-27

Last Posted Date: 2016-11-23

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 210

Registration Number: NCT01441011

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma
Leukemia, Prolymphocytic

Interventions: Drug: auranofin

First Posted Date: 2011-08-18

Last Posted Date: 2016-01-18

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 15

Registration Number: NCT01419691

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States

Flaxseed Lignan (Brevail)

Early Phase 1

Completed

Conditions: Polycystic Ovarian Syndrome

Interventions: Drug: Birth control
Drug: Birth control plus Brevail

First Posted Date: 2011-07-18

Last Posted Date: 2016-01-08

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 9

Registration Number: NCT01396369

Locations: 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States

Axillary Reverse Mapping

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Procedure: Injection of isotope
Procedure: Axillary lymph node dissection

First Posted Date: 2011-06-27

Last Posted Date: 2017-01-10

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 210

Registration Number: NCT01381315

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Qigong Exercise May Benefit Patients With Fibromyalgia

Not Applicable

Completed

Conditions: Fibromyalgia

Interventions: Behavioral: Intervention Group

First Posted Date: 2011-04-12

Last Posted Date: 2016-07-04

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 35

Registration Number: NCT01333566

Locations: 🇺🇸
University Of Kansas Medical Center, Kansas City, Kansas, United States

Changing Talk to Reduce Resistiveness to Care

Not Applicable

Completed

Conditions: Dementia

Interventions: Behavioral: Resident
Behavioral: Staff

First Posted Date: 2011-03-28

Last Posted Date: 2017-02-13

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 202

Registration Number: NCT01324219

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Motivational Interviewing (MI) for African Americans With Peripheral Arterial Disease (PAD)

Not Applicable

Completed

Conditions: Peripheral Arterial Disease

Interventions: Behavioral: PACE
Behavioral: Motivational Interviewing

First Posted Date: 2011-03-23

Last Posted Date: 2017-01-12

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 174

Registration Number: NCT01321086

Locations: 🇺🇸
KU School of Medicine-Wichita, Wichita, Kansas, United States
🇺🇸
Clinical and Translational Science Unit, Fairway, Kansas, United States

Hospitalized Smokers

Not Applicable

Completed

Conditions: Hospitalized Smokers

Interventions: Other: Fax
Other: Warm Hand-off

First Posted Date: 2011-03-01

Last Posted Date: 2016-04-26

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 1054

Registration Number: NCT01305928

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Irinotecan
Drug: BKM120

First Posted Date: 2011-02-25

Last Posted Date: 2017-01-06

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 20

Registration Number: NCT01304602

Locations: 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Lapatinib and RAD-001

First Posted Date: 2011-01-26

Last Posted Date: 2017-02-08

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 23

Registration Number: NCT01283789

Locations: 🇺🇸
University of Kansas Medical Centner, Kansas City, Kansas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy